MODERATOR
:
M. Allene Carr-Greer, MT(ASCP)SBB, Director, Regulatory Affairs, AABB
SPEAKER
:
Dr. Susan Stramer, PhD, Vice President, Scientific Affairs, American Red Cross Biomedical Services
Description
Since the implementation of West Nile virus nucleic acid testing in 2003, it has been recognized that 25 to 30 percent of WNV RNA-confirmed positive donors have viral loads that are too low to be detected by routine minipool NAT performed in pools of six to 16. Therefore, criteria have been developed for conversion from MP NAT to the more sensitive individual donation NAT in locations experiencing localized epidemics. The history of these triggers (criteria for the conversion from MP to ID NAT) and detriggering (resumption of MP NAT) will be discussed, and information will be provided on the validation process for the 2007 trigger. In addition, there will be an overview of various approaches being taken by several blood organizations for the 2008 season. Critical terms as well as data regarding confirmatory testing will be defined.
-
Define terms used for WNV testing and tracking national data.
-
Discuss confirmatory strategies.
-
Discuss the validation of the 2007 trigger and testing options for 2008.
-
Review the development of triggering and detriggering criteria used for prior seasons (2003-07).
| CE Category | CE Value |
|---|
|
California Clinical Laboratory Personnel |
1.5 |
|
California Nurse |
1.8 |
|
Florida Laboratory Personnel |
1.8 |
|
General Attendee |
1.5 |
|
Physician |
1.5 |
Please note: Continuing education (CE) credit is available for online offerings only. Individuals that purchase CD-ROMs will not receive CE credit for the programs they view.